+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase Not Applicable
Age: 18Years - 60Years
All Genders
ID07331987

Study of Probiotics and Escitalopram for Treating Mild-to-Moderate Anxiety and Depression in Adults Aged 18 to 60

Led by Moon (Guangzhou) Biotechnology Co., Ltd. · Updated on 2026-06-29

60

Participants Needed

1

Research Sites

8 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the effects of probiotics combined with Escitalopram in adults aged 18 to 60 with mild-to-moderate anxiety depression. This randomized, double-blind, placebo-controlled study aims to compare anxiety, depression, and sleep outcomes between groups over a 3-month treatment period plus a 1-month follow-up. The study also investigates safety and mechanisms by analyzing serum biomarkers, gut microbiota, and related metabolites. Participants are assigned to one of two groups one receiving probiotics plus Escitalopram and the other receiving placebo plus Escitalopram. Both probiotics and placebos are taken orally once daily at specified dosages for 3 months. Escitalopram Oxalate Tablets are also given daily at 10 mg for 3 months. The 1-month follow-up period includes assessments without additional treatment. During the study, participants will be assessed at baseline, Day 30, Day 90 end of treatment, and Day 120 follow-up using scales for depression HAM-D-24, anxiety HAM-A, sleep quality PSQI, and gastrointestinal symptoms GSRS. Researchers will monitor safety and collect biological samples to analyze changes in biomarkers and gut microbiota. Total participation lasts approximately 4 months including treatment and follow-up.

CONDITIONS

Brief Title

Efficacy and Safety of Probiotics for Anxiety Depression

Research Team

B

Baojia Huang

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here